Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$276M
| $223K | ﹤0.01% |
+8,300
| New | +$328K |
|
3077
Lineage Cell Therapeutics
LCTX
$284M
| $222K | ﹤0.01% |
+268,400
| New | +$267K |
|
3078
Theriva Biologics
TOVX
$10.3M
| $221K | ﹤0.01% |
2,755
+428
| +18% | +$48.7K |
|
3079
Atara Biotherapeutics
ATRA
$76.9M
| $218K | ﹤0.01% |
+1,024
| New | +$325K |
|
3080
Interparfums
IPAR
$3.95B
| $218K | ﹤0.01% |
+4,713
| New | +$294K |
|
3081
Organogenesis Holdings
ORGO
$305M
| $218K | ﹤0.01% |
67,600
+32,300
| +92% | +$138K |
|
3082
Sol-Gel Technologies
SLGL
$288M
| $218K | ﹤0.01% |
3,085
+1,586
| +106% | +$176K |
|
3083
Global X Lithium & Battery Tech ETF
LIT
$1.57B
| $217K | ﹤0.01% |
+10,000
| New | +$277K |
|
3084
Tonix Pharmaceuticals
TNXP
$179M
| – | – |
-1
| Closed | -$663K |
|
3085
Energy Fuels
UUUU
$3.11B
| $217K | ﹤0.01% |
+184,200
| New | +$258K |
|
3086
Yatra Online
YTRA
$52.6M
| $217K | ﹤0.01% |
210,900
+31,700
| +18% | +$89.4K |
|
3087
Zedge
ZDGE
$38.8M
| $217K | ﹤0.01% |
246,714
+7,700
| +3% | +$10.6K |
|
|
MYOV
3088
DELISTED
Myovant Sciences Ltd.
MYOV
| $217K | ﹤0.01% |
+28,700
| New | +$322K |
|
3089
iShares Select Dividend ETF
DVY
$23.5B
| $213K | ﹤0.01% |
+2,900
| New | +$277K |
|
|
LINX
3090
DELISTED
Linx S.A.
LINX
| $212K | ﹤0.01% |
+65,500
| New | +$457K |
|
3091
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.96B
| $209K | ﹤0.01% |
+3,800
| New | +$286K |
|
3092
Armata Pharmaceuticals
ARMP
$173M
| $207K | ﹤0.01% |
66,727
-7,427
| -10% | -$25.6K |
|
3093
iShares Russell Mid-Cap ETF
IWR
$57B
| $207K | ﹤0.01% |
+4,800
| New | +$264K |
|
3094
Oak Valley Bancorp
OVLY
$281M
| $207K | ﹤0.01% |
13,173
+200
| +2% | +$3.42K |
|
3095
Transocean
RIG
$5.69B
| $207K | ﹤0.01% |
178,597
-1,668,603
| -90% | -$6.51M |
|
3096
Solid Biosciences
SLDB
$859M
| $207K | ﹤0.01% |
5,770
+1,901
| +49% | +$94.1K |
|
3097
Urban Outfitters
URBN
$6.67B
| $206K | ﹤0.01% |
+14,500
| New | +$337K |
|
|
LKCO
3098
DELISTED
Luokung Technology Corp Ordinary Shares
LKCO
| $206K | ﹤0.01% |
1,303
+780
| +149% | +$175K |
|
3099
ProQR Therapeutics
PRQR
$278M
| $203K | ﹤0.01% |
37,000
-46,000
| -55% | -$353K |
|
|
YI
3100
111 Inc
YI
$32.5M
| $203K | ﹤0.01% |
+3,065
| New | +$195K |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.